ArticleInquiry : a journal of medical care organization, provision and financing
Benmelstobart Plus Anlotinib Is Unlikely to Be Cost-Effective for Advanced Renal Cell Carcinoma: An Integrated Disease Burden and Cost-Effectiveness Analysis.
Haiyan Xu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.